J. MATTHEW SINGLETON - 02 Jan 2026 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Role: Director
Signature: /s/ Michael Morneau, as Attorney-in-Fact
Issuer symbol: VKTX
Transactions as of: 02 Jan 2026
Net transactions value: $0
Form type: 4
Filing time: 05 Jan 2026, 20:26:57 UTC
Previous filing: 06 Jan 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
SINGLETON J MATTHEW	Director	C/O VIKING THERAPEUTICS, INC., 9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO	/s/ Michael Morneau, as Attorney-in-Fact	05 Jan 2026	0001243514

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VKTX	Common Stock, par value $0.00001 per share	Award	$0	+3,150	+33%	$0.000000	12,650	02 Jan 2026	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VKTX	Stock Option (Right to Buy)	Award	$0	+20,400		$0.000000	20,400	02 Jan 2026	Common Stock	20,400	$35.42	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. All shares subject to the RSU shall vest on the one year anniversary of the grant date of the award.